2012-12-17 06:47:07 - Dr. Anne De Groot Speaking at Immunotoxicity Conference San Diego, CA
Dr. Anne De Groot CEO/CSO EpiVax will present the keynote address at the Inaugural Immunogenicity and Immunotoxicity Conference (Jan 31 – Feb 1, 2013 in San Diego, CA)
Immune responses directed against protein therapeutics can directly impact drug safety and efficacy. The ability to predict and reduce immunogenicity of a potential protein therapeutic presents tremendous benefits at every stage of drug development. While many factors contribute to protein immunogenicity, T cell-dependent responses play a critical role. Modulation of T cell responses by blocking up-regulatory receptors, or concomitant treatment with cytotoxic drugs has also been attempted with varying degrees of success. Tregitopes have now been demonstrated to reduce immune response to antigens in an antigen-specific manner.
The ability to analyze, predict, and
modify the immunogenicity of a protein expands the available strategies for mitigating therapeutic protein immunogenicity, enables quality by design for drugs in development and improvement of licensed biologics to create biobetters.
The Inaugural Immunogenicity and Immunotoxicity conference will bring together a mix of academic and industry experts from leading affiliations (such as MedImmune, Roche, Ambryx, Aegis Therapeutics, Antitope, Epiontis, Amgen, EpiVax, Ablynx, Eleven Biotherapeutics, Bayer HealthCare and more) to cover many current and relevant aspects of Immunogenicity and Immunotoxicity.
This conference is also part of the 2nd Novel Cancer Therapeutic Summit, which consists of this track and three other tracks:
1) 5th Immunotherapeutics and Immunomonitoring
2) 11th Cytokines and Inflammation
3) 2nd Allergy & Respiratory Drug Discovery
For more information, please visit www.gtcbio.com